TABLE 3.
Efficacy of individual IL-17 inhibitors for the treatment of nonplaque psoriasis phenotypes from the AAD-NPF guidelines
| PSORIASIS PHENOTYPE | SECUKINUMAB | IXEKIZUMAB | BRODALUMAB |
|---|---|---|---|
| Erythrodermic | C | B | * |
| Generalized pustular | * | B | * |
| Palmoplantar | A | * | |
| Scalp | B | B | * |
| Nail | A | B | * |
| Inverse | * | ||
| Psoriatic arthritis | A | A | * |
Scoring is based on strength of recommendation taxonomy; A: Recommendation based on consistent and good-quality patient-oriented evidence; B: Recommendation based on inconsistent or limited-quality patient-oriented evidence; C: Recommendation based on consensus, usual practice, disease-oriented evidence, case series for studies of treatment or screening, and/or opinion
*Drug has shown efficacy but was not given a graded strength of recommendation